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Abstract 
Background: Worldwide, hepatitis C virus (HCV) infection is a serious public health disease unlike hepatitis A and 
B, however there is currently no vaccine against HCV available. Thus, extensive studies are under way to design 
new and effective treatments against HCV. Core protein is a component of HCV particle which is the first antigen 
recognized by the immune system. Beside protective properties of core protein, anti –core antibodies can be used to 
monitor the disease progress. The purpose of the present study was to isolate and clone the core (C) gene from HCV 
genotype 1a in an attempt to construct a recombinant vector and subsequently evaluate its expression in a cell culture 
system. Materials and Methods: RNA genome of HCV genotype 1a was extracted from the blood of an infected 
patient. Complementary DNA (cDNA) was synthesized. HCV 1a core gene was amplified by PCR using specific 
primers and it was cloned into a eukaryotic expression vector. Huh7.5 cells were transfected by the designed 
recombinant vector and the cellular expression of the core gene was confirmed by RT-PCR. Results: Recombinant 
pcDNA3.1 (+) vector containing the HCV core gene with approximate size of 576bp was successfully designed. 
RT-PCR was used to confirm the expression of core antigen in Huh7.5 cell line. Conclusion: The results showed 
that the core gene was successfully isolated from HCV genotype 1a and was cloned into the eukaryotic expression 
vector. This recombinant vector effectively replicated in Huh7.5 cell line, and its protective and therapeutic effects 
can be examined in further investigations. 
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Introduction 
Hepatitis C virus (HCV) is an enveloped, 
single stranded positive sense RNA virus that belongs 
to Flaviviridae family. HCV infection afflicts more 
than 170 million people worldwide. In the majority of 
patients with HCV acute infection, the disease 
progresses to the chronic form with severe 
complications such as liver cirrhosis and carcinoma 
that leads to global death of thousands of people. The 
prevalence of infection varies in different regions of 
the world. In some areas, like Egypt, the prevalence is 
as high as about 22% (1, 2).  
It is estimated that around 2 million people in 
Europe are infected with HCV. The prevalence of 
HCV infection is higher in Africa compared to that of  
America and Europe (1, 2). Injecting drug users and 
infected blood recipients are more at risk. So far, at 
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least Seven genotype (1, 2, 3, 4, 5, 6 &7) and several 
subtypes (a, b, c, d, etc) of HCV have been defined. 
These genotypes  have different global distributions, 
disease progression, and response status to antiviral 
treatments (3). The course of medical treatments in 
patients with genotype 2 or 3 is 24 weeks, while 
patients with genotype 4, 1 need 48 weeks of 
treatment. Among these, genotype 1 strains are less 
responsive to interferon therapy. HCV genome 
encodes at least 10 proteins. The core protein and the 
envelope glycoproteins E1 and E2 are the structural 
proteins while the others are non-structural proteins 
(4, 5). 
HCV core protein is a multifunctional protein 
which has roles in RNA replication, virion self-
assembly, and the production of HCV-like particles. 
Envelope proteins including the core, E1 and E2 of 
HCV are seemingly the main targets for inducing 
antibodies against HCV. These antibodies can be used 
as therapeutic, diagnostic and other downstream 
purposes (6, 7). 
IC41 is a new vaccine based on a synthetic 
core, NS3, and NS4 peptides that stimulated 
efficiently the immune system in volunteers in phase 
2 clinical trials. The results indicated   the importance 
of core protein in development of new generations of 
vaccine (8). 
Several other studies have shown that the 
detection of core antigen is a cost effective (compared 
to the highly cost routine test of RNA quantification) 
alternative way to the diagnosis and monitoring the 
HCV infection because in more than 50 % of infected 
individuals, the anti-core antibodies are present. The 
measurement of HCV-core antigen can be a reliable 
indicator for active infection (9, 10).  
In present study, a recombinant vector that 
expresses the highly conserved HCV core gene was 
constructed and its expression was confirmed in a 
Huh7.5 cell line. This vector can be used for future 
studies such as attempts on its purification, vaccine 
design and diagnostic tests. 
Methods 
RNA extraction and cDNA synthesis. A blood 
sample was obtained from a patient infected with 
HCV genotype 1a. The procedure for RNA extraction 
was performed according to the manufacturer’s 
recommendations (Qiagen,USA). Purified RNA was 
used to synthesis the cDNA, according to 
manufacturer’s recommendations (Pars Tous, Iran). 
Polymerase chain reaction (PCR) for 
isolation of core gene. A pair of specific primers was 
designated by Gene Runner (Version 3.05, Hastings 
Software Inc.) and DNAMAN (version 5.2, 
LynnonBiosoft,) software. 
The full-length of core gene was amplified by 
polymerase chain reaction (PCR) from cDNA 
genome. 5- 
TAGACCAAGCTTCATGAGCACGAATCCTAAA
CCT-3 as forward primer contained HindIII 
restriction site and 5- 
ATACATGGATCCttactaGGCCGA(A/G)CAGAGG
GTGG-3 as reveres primer contained BamHI 
restriction site and stop codon were used for 
amplification of core gene. Under lined letters in 
forward and reveres primers represent HindIII and 
BamHI restriction sites. 
The PCR reaction mixture for the amplification 
of core gene contained 10 ng DNA sample, 2.5 mM 
MgCl2, 0.5 mM each dNTPs, 10 pmol of each primer, 
1 unit Taq polymerase (Sinaclon, Iran). The PCR 
program was as follows: initial denaturation stage of 
95°C for 5 min, followed by 35 cycles at elongation 
stage(95°C for 1 min, 58°C for 1 min, 72°C for 1 
min), and a  final extension of 72°C for 20 min (11, 
12).  
Cloning of the core gene into an expression 
plasmid. Isolated PCR products, along with 
pCDNA3.1+ vector, were digested with HindIII and 
BamHI restriction enzymes. The digested vector and 
PCR products were fused together as described 
previously (13). Competent E. coli bacteria strain 
JM109 were prepared based on Sambrook protocols 
(14) and were then transformed by the recombinant 
vector. Colony PCR, using the above-mentioned 
primers, and the sequencing method were used to 
confirm the accuracy of the cloning procedure. 
 
Cells. Huh-7.5 cells (American Type Culture 
Collection, USA) were cultured in Dulbecco's 
modified Eagle's medium (DMEM) enriched with 
10% fetal bovine serum (Invitrogen, USA), 0.2% 
sodium bicarbonate (Sigma, USA), 100U/ml 
penicillin (Invitrogen, USA), and 100µg/ml 
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streptomycin (Invitrogen, USA)  at  37°C in a 5% 
CO2 atmosphere (12). 
Transfection. DMRIE-C reagent (Invitrogen, 
USA) was used for the transfection of Huh-7.5 cells. 
The transfection was performed as described 
previously (12). Briefly, 3 × 105 Huh-7.5 cells were 
cultured in a 6-well tissue culture microplate 
containing 2 ml of complete DMEM media and the 
microplate was incubated at 37°C under 5% CO2 
condition. After 24h, the medium was discarded and 
was replaced with 2 ml of Opti-media (Invitrogen, 
USA). In the next step, the microplate was incubated 
at 37°C under 5% CO2 condition for 30 minute. The 
transfection mixture was prepared according to the 
manufacturer’s instructions (Invitrogen, USA) and the 
transfection was performed. Seventy-two hours post 
transfection, the culture media and the transfected 
cells were collected in order to confirm the expression 
of recombinant plasmid containing HCV core gene by 
RT-PCR. 
RT-PCR. To confirm the in vitro expression of 
recombinant plasmid containing HCV core gene, 72h 
after transfection, the cells were treated with 0.5 ml 
trypsin (Invitrogen, USA) incubated for 10 min and 
the cells were collected for RNA extraction. 
RNAXplus (CinnaGen, Iran) was used for the total 
RNA extraction as described previously (15, 16), and 
DNase I (Fermentas, Germany) was used to  eliminate  
the transfected plasmids. Purified RNA was used for 
cDNA synthesis using the cDNA synthesis kit and 
oligo-dT primer (Pars Tous, Iran) as template in the 
PCR reaction. PCR was performed as described 
above.  
Results 
Core gene was isolated from HCV genome by 
using specific primers and then cloned into 
pCDNA3.1+vector (Figure 1). 
Huh7.5 cell line was transfected with the 
recombinant vector encoding the Core antigen of 
HCV genotype 1a. The gene expression was 
confirmed by RT-PCR (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
Hepatitis C virus (HCV) is a dangerous human 
pathogen that causes chronic liver disease and   is a 
serious public health problem throughout the world. It 
is estimated that about 3% of the world population is 
infected with HCV and most of infected individual 
unable to resolve the virus so HCV is the leading 
cause of hepatocellular carcinoma (HCC) around the 
world. The infection is more prevalent in the 
 
 
Figure 1. Agarose gel electrophoresis of core 
PCR product. Lane 1: PCR product of 
amplifying core gene 576bp; Lane 2: 100bp 
DNA size marker. 
 
 
Figure 2. Confirming core gene expression by 
detecting the core mRNA in transfected Huh-
7.5 cells using RT-PCR. Lane1:100bp DNA 
marker; Lane2: non-transfected cells as 
negative control; and Lanes 3 and 4: 600bp 
fragment of transfected cells with recombinant 
vector. 
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developing countries with about 1.5 million deaths 
per year and intravenous drug use and blood 
transfusion are the main routes of acquisition the 
infection. Therefore it is necessary to develop new 
therapeutic approaches to cure or at least to prevent 
further progression to chronicity (3, 17, 18). HCV has 
at least 6 different genotypes and 30 subtypes. Some 
HCV subtypes such as 1a, 1b, 2a, 2b are spread all 
over the world. High mutation rates in the HCV 
genome, which generates new genotypes and sub 
genotypes, lack of suitable cell culture systems and 
proper animal model has hampered the progress in the 
development of effective vaccines and drugs (2, 19-
21).  
The genetic diversity in glycoproteins E2 and 
E1 are very high, while in genetic regions associated 
with NS5B, core NS5A genes is more stable. So far, 
effective immune responses in clearing the HCV 
infection have not been clearly identified. However, 
many studies have shown that both CD4 and CD8 T 
cells have important role in eliminating the virus 
during infection. Disability of immune cells to 
produce IFN-γ, reduction in the production of 
antiviral cytokines, dysfunction of dendritic cells, 
development of suppressor T cells, along with further 
viral mutations paves the way for the virus to evade 
the immune system and progress to chronic infection 
(22-24). 
HCV is responsible for 40 -60% of chronic 
liver infections. In about 30% of the cases, the 
infection progresses to cirrhosis and fibrosis. Costly 
treatment options, adverse side effects, genetic 
variation in different viral strains and host factors can 
restrict the effectiveness of drug treatments. This 
necessitates the development of an effective vaccine 
to control infection (23, 25, 26). Among different 
HCV genotypes, the core antigen is much conserved 
and can be the proper candidate for vaccine 
development against HCV infection.  
E1, E2, and core proteins of HCV are structural 
proteins that may induce the production of 
neutralizing antibodies. Therefore, core protein might 
serve as a vaccine candidate. Currently, extensive 
efforts are taken to establish effective vaccines 
against the HCV virus. The purpose of designing a 
vaccine against this virus can be divided into 
preventive vaccine or therapeutic vaccines so 
recognition most immunogenic antigens of the HCV 
antigens is very important. Several vaccine 
candidates,  based on these antigens, are under 
evaluation in phase I / II human clinical trials (27, 
28).  
Recent studies reveal that core antigen is able 
to induce both humoral and cellular immune 
responses in natural infection. Antibodies upon core 
protein during the acute phase of infection is the  first 
antibodies to appear against HCV antigens however 
cell mediate immunity  paly critical role in controlling 
virus replication so that  generation core-specific CTL 
cells is correlated with lower levels of viremia and 
restrain infection(29). Nowadays many attempts have 
been devoted for the development of efficient 
therapies against HCV infection. Studies have shown 
that the vaccination with DNA vaccines could be a 
reliable and efficient mode of vaccination.  The DNA 
vaccines are currently studies in this field. In a study, 
Ajorloo et al provided evidence that the anti-Core 
antibody is a  suitable marker to discriminate people 
who have had cirrhosis from  non-cirrhotic people as 
the titer of anti-Core antibody is significantly higher 
in patients with cirrhosis (30, 31). 
Other similar studies indicate that the Core 
antigen is a valuable antigen to develop serological 
assays for monitoring HCV infection. Previous 
studies have shown that the effective immune 
responses against HCV are neutralizing antibodies 
and cell mediate immunity. Core antigen, as a 
structural antigen, induces neutralizing antibodies and 
promote T cell responses especially cytotoxic T cell 
(CTL). HCV has broad genetic diversity and so 
prepared vector in this study may become a basis for 
development DNA or viral-based vaccine to 
overcome viral immune escape both in the 
prophylactic or therapeutic settings (32-34). 
In a study by Dueñas-Carrera et al.  a DNA 
vaccine encoding core, E1 and E2 proteins and 
individually constructed and then administered to 
BALB / c mice. High titer of antibody and the 
production of IFN-γ as a marker for cell mediated 
immune responses in mice were showed that the DNA 
vaccine encodes core- E1 - E2 protein in compared to 
the vectors that only express E1 or E2 antigen would 
have much immunogenicity (35, 36). 
Alvarez-Lajonchere showed that the co-
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administration of core protein with DNA vaccine 
encoding the envelope proteins and core (CIGB-230) 
can stimulate and significantly increase the immune 
responses against the DNA vaccine. 
 Also Alvarez-Lajonchere showed in  a phase 1 
clinical trial that the intra-muscular injection of 
CIGB-230 vaccine in patients with chronic HCV 
infection who were non-responders to  treatment with 
ribavirin and interferon gamma was very successful in 
such a way  that after the last injection, high titers of  
HCV-specific antibodies and  the generation of virus-
specific T cells producing IFN-γ were observed. In 
the final course of treatment, 33.3% of patients 
showed cellular immune responses against core 
protein. This study showed that CIGB-230 vaccine is 
a good candidate for the treatment of patients with 
chronic HCV infection (37-39). 
Beside the issue of vaccine, core antigen is a 
diagnostic marker. There are several for identifying 
HCV infection. For instance, anti-HCV antibodies 
and the level of viral replication can be studied by an 
enzyme immune assay (EIA) and nucleic acid testing 
(NAT). However, both of them have several 
advantages and disadvantages. For instance, false-
positive or false-negative results can be achieved by 
EIA test and it is not possible to distinguish new 
infection from the past cleared infections. Nucleic 
acid testing (NAT) like Real time PCR has high 
specificity and sensitivity for quantifying HCV RNA 
in blood and is used to monitor the progress of the 
treatment but it is very costly and it is not readily 
available in some developing countries.  These are the 
reasons why in recent years several tests based on 
core antigen have been developed to monitor HCV 
infection so recently a commercial test based on HCV 
core antigen to confirm infection has been developed. 
This test in compared to HCV RNA assays is more 
cost effective and easier to perform. (40-43).  
In the current study a vector encoding the core 
gene of HCV was developed in order to analyze its 
expression in a cell culture system. This construct 
could be used as a basis for designing new 
generations of vaccines against HCV 1a genotype in 
further studies. 
 
 
 
Conclusions 
Due to the capacity of Core antigen in 
stimulating immune responses, a recombinant vector 
containing core gene from HCV genotype 1a was 
constructed and its expression was confirmed. 
Successful cloning provides a foundation for 
development of new DNA vaccines against HCV 
infection. Further studies are needed in order to 
evaluate immune responses. 
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